PROCEPT BioRobotics Corporation Reports Third Quarter 2024 Financial Results
Intellectia.AI
PROCEPT BioRobotics Corporation Reports Third Quarter 2024 Financial Results
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) – PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a surgical robotics company advancing patient care with transformative urology solutions, has announced its unaudited financial results for the third quarter ending September 30, 2024.
Key Financial Metrics
Metric | Q3 2024 | Q3 2023 | YoY Change | Consensus Estimates |
---|---|---|---|---|
Total Revenue | $58.4 million | $35.2 million | +66% | $53.18 million |
Gross Margin | 63.2% | 53.8% | +9.4 pp | - |
Net Loss | $21.0 million | $24.6 million | - | - |
Adjusted EBITDA Loss | $12.4 million | $19.4 million | - | - |
Interpretation: PROCEPT BioRobotics Corporation witnessed a significant year-over-year revenue increase of 66% for Q3 2024, surpassing consensus estimates with $58.4 million compared to $53.18 million. The company also achieved a record gross margin of 63.2%, a notable improvement from 53.8% a year earlier, primarily due to enhanced overhead absorption and a rise in average selling prices of U.S. robotic systems. The net loss decreased to $21.0 million, indicating improved operational efficiency despite ongoing expansion efforts.
Revenue Performance by Segment
Segment | Q3 2024 Revenue | YoY Change |
---|---|---|
U.S. Handpiece & Consumables | $29.6 million | +74% |
U.S. System & Rental | $19.6 million | +46% |
International Revenue | $6.2 million | +122% |
Interpretation: The strong growth in U.S. handpiece and consumables revenue, which rose by 74%, highlighted increased demand for PROCEPT BioRobotics products. U.S. system and rental revenue incrementally increased by 46%, while international sales surged by 122%, reflecting successful global market penetration and the effectiveness of the company's strategic initiatives.
Key Developments and Operational Highlights:
- HYDROS Launch: Successfully launched and delivered the HYDROS Robotic System in the third quarter following FDA clearance in August.
- Increased FY2024 Guidance:
- Revenue projected between $222.5 million and $223.0 million.
- Gross margin guidance raised to 61%.
- Adjusted EBITDA loss guidance reduced to $60.0 million from $67.5 million.
- Improved Customer Relations: Effectively managed customer relationships during the implementation phase of new systems.
Executive Comments: Reza Zadno, Chief Executive Officer, praised the PROCEPT team's efforts in launching the HYDROS system and highlighted significant progress in maintaining customer relations during a pivotal growth phase for the company. Zadno emphasized the revenue growth of 66% year-over-year and the achievement of record gross margins as indicative of the company's successful strategic execution.
Forward Guidance: PROCEPT BioRobotics has provided an updated revenue range of $222.5 million to $223.0 million for the full year 2024, with increased forecasted gross margins and an improved Adjusted EBITDA loss estimate reflective of operational efficiencies and market growth prospects.
Stock Price Movement: Following the release of the earnings report, PROCEPT BioRobotics observed a significant stock price increase of approximately 17.3%, suggesting strong investor confidence in the company's performance and future outlook.
For more in-depth analysis and insights, stay tuned with our platform to stay ahead of the market.
Share
Want more financial insights delivered directly to your inbox?
Subscribe now and receive handpicked financial news, insights, and trending topics.